Improvac

Authorised

This medicine is authorised for use in the European Union

gonadotropin releasing factor (GnRF) analogue-protein conjugate

Overview

Up-to-date information on this veterinary medicinal product is available on the Veterinary Medicines Information website.

Improvac : EPAR - Summary for the public

Product information

Improvac : EPAR - Product Information

Improvac : EPAR - All Authorised presentations

Product details

• Name of medicine:
  Improvac
• Active substance:
  synthetic peptide analogue of GnRF conjugated to diptheria toxoid
• International non-proprietary name (INN) or common name:
  gonadotropin releasing factor (GnRF) analogue-protein conjugate

Pharmacotherapeutic group

Immunologicals for suidae

Authorisation details

• EMA product number:
  EMEA/V/C/000136

Assessment history

Changes since initial authorisation of medicine

Improvac : EPAR - Procedural steps taken and scientific information after authorisation

CVMP post-authorisation summary of positive opinion for Improvac (VRA-0039-G)

Adopted Reference Number: EMA/CVMP/721187/2022

Improvac-V-C-136-II-0036 : EPAR - Assessment Report - Variation

Adopted Reference Number: EMA/746574/2021

CVMP post-authorisation summary of positive opinion for Improvac (II-0036)

Adopted Reference Number: EMA/CVMP/714359/2021

Improvac-V-C-136-II-09 : EPAR - Assessment Report - Variation

Adopted

CVMP post-authorisation summary of positive opinion for Improvac

Adopted Reference Number: EMA/CVMP/559849/2010

Improvac-V-C-136-II-07 : EPAR - Assessment Report - Variation

Adopted

Initial marketing authorisation documents

Improvac : EPAR - Scientific Discussion

Improvac : EPAR - Procedural steps taken before authorisation

Committee for medicinal products for veterinary use summary of opinion: Improvac: Gonadotropin releasing factor (GNRF) analogue-protein conjugate

Adopted Reference Number: EMEA/CVMP/18480/2009